Sanofi India Q2 profit rises 20% as diabetes portfolio lifts margins
Sanofi India reported Q2 net profit of ₹83.5 crore, up 20.1% year on year, as its insulin portfolio grew 14%. Revenue rose 7.7% to ₹437.7 crore and EBITDA margin expanded to 26.3% from 23.4%, aided by higher public-sector business.
What happened
Sanofi India reported Q2 profit growth of 20% and margin expansion, led by 14% growth in its insulin portfolio. Public-sector revenue rose 70% as new Toujeo and
Key facts
- Q2 net profit: ₹83.5 crore, up 20.1% YoY
- Revenue from operations: ₹437.7 crore, up 7.7% YoY
- EBITDA: ₹115.3 crore, up 21.5% YoY
- EBITDA margin: 26.3%, versus 23.4% a year earlier
- Insulin portfolio growth: 14%
- Basal insulin analogue market share: 58% by value and 61% by volume
- Public-sector business revenue growth: 70%
Why this matters
Sanofi India’s results reinforce the strategic value of diabetes portfolios and public-sector distribution partnerships for margin-accretive healthcare growth.
What to watch
- Insulin portfolio growth versus the reported 14% Q2 pace.
- EBITDA margin retention around or above 26.3%.
- Share of revenue from public-sector and institutional tenders.
- Receivables and inventory trends tied to government-business expansion.
- Competitive pricing, launches and market-share changes in India diabetes therapies.
- Whether revenue growth accelerates from the reported 7.7% Q2 rate.
- Prioritize insulin portfolio availability and physician/patient engagement to defend diabetes-market share.
- Pursue public-sector business selectively, balancing volume gains against tender-driven pricing and working-capital risk.
- Use stronger profitability to support targeted launches, lifecycle extensions and higher-return chronic-care investments.
- Highlight margin drivers and public-sector revenue concentration in investor communication to set expectations for quarterly volatility.